Barrington Upgrades Perficient to Outperform From Market Perform With $77 Price Target
Alliance Global Partners: Downgraded Perfusion (PRFT.US) rating from buy to neutral.
Perficient Analyst Ratings
Maxim Group: Downgraded Perfusion (PRFT.US) rating from buy to hold, with a target price of $76.00.
Barrington Research: Lowered the Perfomance (PRFT.US) rating from superior to market to consistent market rating.
Scotiabank: Maintaining the Perfomance (PRFT.US) rating, adjusted from being flat with the market to being flat with the market, and the target price was adjusted from $50.00 to $76.00.
Needham: Downgraded Perfusion (PRFT.US) rating from buy to hold.
Perficient Analyst Ratings
Scotiabank Remains a Hold on Perficient (PRFT)
Perficient Analyst Ratings
Komo: Maintaining the Perfuming (PRFT.US) rating, adjusted from neutral to neutral, and adjusted the target price from $71.00 to $59.00.
Scotiabank Maintains Sector Perform on Perficient, Lowers Price Target to $50
Barrington Research: Maintaining the Perfomance (PRFT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $77.00 to $77.00.
Perficient Analyst Ratings
Alliance Global Partners: Upgraded Perfusion (PRFT.US) rating from neutral to buy rating.
Perficient Analyst Ratings
Guggenheim Initiates Perficient With Neutral Rating, Price Target Is $65
Perficient Analyst Ratings
Buy Rating Affirmed for Perficient Amid Strong Growth Prospects and Attractive Valuation
Barrington Research Reiterates Outperform on Perficient, Maintains $77 Price Target